Vanessa
Roldan Schilling
Catedraticos de Universidad Vinculados H.V.Arrixaca
Javier
Corral De La Calle
Profesor Titular de Universidad Vinculado H.U.M.M.
Publicaciones en las que colabora con Javier Corral De La Calle (43)
2023
-
Factor XI in Carriers of Antiphospholipid Antibodies: Elevated Levels Associated with Symptomatic Thrombotic Cases, While Low Levels Linked to Asymptomatic Cases
International Journal of Molecular Sciences, Vol. 24, Núm. 22
2021
-
Anticoagulant therapy in patients with congenital FXI deficiency
Blood Advances, Vol. 5, Núm. 20, pp. 4083-4086
2020
-
ALG12-CDG: An unusual patient without intellectual disability and facial dysmorphism, and with a novel variant
Molecular Genetics and Genomic Medicine, Vol. 8, Núm. 8
-
Factor XII in PMM2-CDG patients: Role of N-glycosylation in the secretion and function of the first element of the contact pathway
Orphanet Journal of Rare Diseases, Vol. 15, Núm. 1
2018
-
Assessment of two contact activation reagents for the diagnosis of congenital factor XI deficiency
Thrombosis Research, Vol. 163, pp. 64-70
2017
-
High incidence of FXI deficiency in a Spanish town caused by 11 different mutations and the first duplication of F11: Results from the Yecla study
Haemophilia, Vol. 23, Núm. 6, pp. e488-e496
2016
-
Genotype-guided therapy improves initial acenocoumarol dosing: Results from a prospective randomised study
Thrombosis and Haemostasis, Vol. 115, Núm. 1, pp. 117-125
-
Hypoglycosylation is a common finding in antithrombin deficiency in the absence of a SERPINC1 gene defect
Journal of Thrombosis and Haemostasis, Vol. 14, Núm. 8, pp. 1549-1560
2015
-
A new method to quantify β-antithrombin glycoform in plasma reveals increased levels during the acute stroke event
Thrombosis Research, Vol. 136, Núm. 3, pp. 634-641
2014
-
Effect of VKORC1, CYP2C9 and CYP4F2 genetic variants in early outcomes during acenocoumarol treatment
Pharmacogenomics, Vol. 15, Núm. 7, pp. 987-996
2013
-
Association of the thrombomodulin gene c.1418c7gt;t polymorphism with thrombomodulin levels and with venous thrombosis risk
Arteriosclerosis, Thrombosis, and Vascular Biology, Vol. 33, Núm. 6, pp. 1435-1440
-
Creating a genotype-based dosing algorithm for acenocoumarol steady dose
Thrombosis and Haemostasis, Vol. 109, Núm. 1, pp. 146-153
-
Novel Associations of VKORC1 Variants with Higher Acenocoumarol Requirements
PLoS ONE, Vol. 8, Núm. 5
2012
-
miR-133a regulates Vitamin K 2,3-epoxide reductase complex subunit 1 (VKORC1), a key protein in the Vitamin K cycle
Molecular Medicine, Vol. 18, Núm. 11, pp. 1466-1472
2011
-
Identification of miRNAs as potential modulators of tissue factor expression in patients with systemic lupus erythematosus and antiphospholipid syndrome
Journal of Thrombosis and Haemostasis, Vol. 9, Núm. 10, pp. 1985-1992
2010
-
Deep venous thrombosis or pulmonary embolism and factor V leiden: Enigma or paradox
Haematologica
-
Influence of the F12-4 C>T polymorphism on hemostatic tests
Blood Coagulation and Fibrinolysis, Vol. 21, Núm. 7, pp. 632-639
-
Pharmacogenetics of acenocoumarol in patients with extreme dose requirements
Journal of Thrombosis and Haemostasis, Vol. 8, Núm. 5, pp. 1012-1017
-
Study of 18 functional hemostatic polymorphisms in mucocutaneous bleeding disorders
Annals of Hematology, Vol. 89, Núm. 11, pp. 1147-1154
-
Synergism between factor XII -4C>T and factor XIII Val34Leu polymorphisms in fibrinolytic therapy in acute myocardial infarction
Thrombosis and Haemostasis